Last reviewed · How we verify
NCT07298590
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
EARLY_PHASE1 trial testing CD19/BCMA CAR NK in IgG4 Related Disease in 18 participants. Not yet recruiting.
26 June 2028
Quick facts
| Lead sponsor | Changhai Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 30 December 2025 |
| Primary completion | 26 June 2028 |
| Estimated completion | 26 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19/BCMA CAR NK — full drug profile →
Conditions studied
- IgG4 Related Disease — all drugs for IgG4 Related Disease →
Sponsor
Changhai Hospital
Who can join
Adults 18 to 70, any sex, with IgG4 Related Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07298590
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for IgG4 Related Disease
Currently open trials in the same condition.
- NCT07061938 — Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease · Phase 1, PHASE2 · recruiting
- NCT07535554 — The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Com · Phase 2, PHASE3 · recruiting
- NCT07148791 — Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease · Phase 2 · recruiting
- NCT07068165 — A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease · Phase 2, PHASE3 · recruiting
- NCT06361745 — Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases · NA · recruiting
Other Changhai Hospital trials
Trials by the same sponsor.
- NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
- NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07298590 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07298590.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing